AstraZeneca Pharmaceuticals has appointed healthcare specialist CPR
Worldwide to develop a PR programme in support of a worldwide
surveillance study, which will monitor rates of antibiotic resistance
around the world.
The appointment, which follows a competitive three-way pitch, will see
the agency’s London office support the global activities of the
company’s in-house PR department.
The agency has also been awarded several product briefs relating to the
company’s pain, anaesthesia and infection therapy product areas.
Scott Clark, joint CEO of the agency, said that it was always a
challenge to get media attention for drugs that work in the area of pain
management and anesthesia because of media fatigue.
’On the face of it, it may not seem the most media friendly story, even
though these problems can affect large numbers of people either directly
or indirectly,’ he said.